Urination impaired
Conditions
Interventions
2 mg silodosin daily
4 mg silodosin daily
8 mg silodosin daily
Sponsors
Kinki University Faculty of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: No abnormalities found in health checkup. Must be capable of making outpatient hospital visits. Written informed consent can be obtained.
Exclusion criteria
Exclusion criteria: Patient with serious comorbid heart disease. Patient with serious comorbid liver disease or total bilirubin level more than 3 mg/dL or AST(GOT) or ALT(GPT) & 2.5 times the upper limit of the reference range. Patient with serious comorbid kidney disease or serum creatinine & more than 1.5 mg/dL. Patient with serious hypotension. Woman who is pregnant, nursing, wishes to become pregnant during the study period, or cannot follow physician's instructions regarding contraception. Patient who has taken another study drug or investigational drug within 1 month prior to beginning this study. Others judged to be unsuited as subjects according to the Principal Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in blood pressure, pulse rate, and electrocardiogram waveform | — |
Secondary
| Measure | Time frame |
|---|---|
| I-PSS, OABSS, Uroflowmetry, PVR | — |
Countries
Japan
Contacts
Public ContactNobutaka SHIMIZU
Kinki University Faculty of Medicine Department of Urology
Outcome results
None listed